The client
A multinational pharmaceutical company with a core focus in cell therapy and immuno-oncology.
Challenge
The company had established a presence in the oncology cell therapy space with numerous clinical development programs and strategic acquisitions which added platform capabilities. In light of the rapidly-accumulating data suggesting the clinical activity – and possibly curative potential – of CAR-T cell therapy in autoimmune and inflammatory diseases (AIID), the company asked Lumanity to assess the opportunity for its cell therapy technology and delineate why and how the company should pursue the development of cell therapy candidates for AIID applications.
Approach
Lumanity built upon an existing deep relationship with the company and addressed the business challenge by:
- Aligning with client development team on the company’s updated cell therapy platforms, portfolio architecture, and purported value proposition for AIID applications through a workshop involving internal experts from Lumanity and key stakeholders from the client side.
- Conducting thorough secondary research and a comprehensive literature review to map the relevant competitive landscape of companies, technologies, indications, and targets positioned to compete at a platform and asset level.
- Engaging with KOLs at the cutting edge of this emerging space to understand the current and evolving competitive landscape, market dynamics, unmet needs, benchmarks for success, and positioning recommendations for the client’s platform.
